In Brief: Miles' Nisocor
Miles' Nisocor: Firm considering outlicensing the calcium channel blocker extended-release nisoldipine, which was approved Feb. 2. Miles says it is "reviewing various commercial options in addition to directly marketing Nisocor," including copromotion and out-licensing. Nisocor was given a "1S" rating by FDA, designating a new molecular entity receiving a standard review. The NDA (20-356) for Nisocor was originally submitted on March 31, 1993. Miles resubmitted the application on Aug. 3, 1994 after receiving a "not approvable" letter from FDA in March 1994. Reasons for rejecting the initial application cited by the agency included inadequate stability data to establish shelf-life of the product and the lack of a stereochemical identity test to demonstrate that the drug is a racemic mixture. Nisocor was approved in tablet strengths of 10 mg, 20 mg, 30 mg and 40 mg...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth